网易首页 > 网易号 > 正文 申请入驻

Eli Lilly's Weight Loss Drug Tirzepatide Approved in China Following Novo No...

0
分享至

TMTPost -- Novo Nordisk A/S’s blockbuster weight loss drug Wegovy is facing direct competition from its arch-rival in China.

AI Generated Image

Eli Lilly & Co. ‘s tirzepatide injection under the brand name Mounjaro, has won approval for use of chronic weight management on July 19, according to a release at the website of China's National Medical Products Administration (NMPA). As the first GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist in the world, Mounjaro is Eli Lilly’s first obesity therapy approved in China, the company said in a statement. Mounjaro is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity (initial BMI≥28 kg/m2) or overweight (initial BMI≥24 kg/m2) with at least one weight-related comorbidity like Hypertension, hyperglycemia, dyslipidemia,Eli Lilly said.

The approval of Mounjaro came after Novo Nordisk said its weekly jab Wegovy was greenlit in China less than a month ago. Wegovy is the world’s first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. Wegovy will soon be available in China but the initial sales will be restricted, so that the influx of Chinese patients doesn’t deplete supply for the rest of the world, Maziar Mike Doustdar, the Danish pharma giant’s chief of international operations, said following the announcement of approval. The official added that Novo wants to ensure that people who start the treatment will keep a steady supply of the drug.

Novo Nordisk is striking a delicate balance as the drugmaker seeks meeting pent-up demand in China while taking advantage of what may only be a brief head start on its U.S. rival Eli Lilly.Besides Mounjaro, Lilly is also co-developing obesity drug called mazdutide with its Chinese partner Innovent Biologics Inc.The drug is anticipated to hit the market next year. Several companies are working on biosimilar versions of Wegovy in a race to get them on market when Novo’s patent expires.

As the world’s second largest economy and the second most populous country, China is a highly promising market for Novo Nordisk and its competitors. It is projected to hold the highest number of overweight or obese people.

More than half of Chinese people age 18 and above are obese or overweight owing to unhealthy diets and static lifestyles, according to a report released by the National Health Commission of China in December, 2020. It showed 34.3% of adult Chinese are overweight and 16.4% are obese.The proportion of the younger population facing weight issues is also alarming. Nearly 20% of youngsters aged 6 to 17 and more than 10% of children younger than 6 are either obese or overweight. The Chinese public health study showed in 2020 that the number of overweight adults in the country is estimated reach 540 million by 2030, 2.8 times higher than 2000 levels. Numbers who are obese are seen jumping 7.5 times to 150 million.

The Wall Street expressed upbeat on the market for weight-loss drugs driven by demand from major economies like China and U.S. The global obesity market is set to reach $130 billion by 2030, up from a prior forecast of $100 billion last October, Goldman Sachs analysts estimated in a note late May. The update “reflects our assessment of the impact of certain events that have occurred since our last published estimate across several key domains that factor importantly in our forecasting assumptions,” the analysts wrote.

China is expected to become a RMB14.9 billion ($2 billion) obesity market by the end of the decade, Chinese news media outlet The Paper reported earlier this month, citing data from Ping An Securities Co. The report cited another China-based securities firm Caitong Securities Co., Ltd that the local market is expected to exceed RMB12 billion in 2025, considering China had 192 million overweight and obese people aged 18 and above as of 2019.

特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。

Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.

相关推荐
热点推荐
特朗普是美国历史上第一位,也是到目前为止唯一一位,当选总统前既没有任何文职政府公职、也没有参军服役经历的总统

特朗普是美国历史上第一位,也是到目前为止唯一一位,当选总统前既没有任何文职政府公职、也没有参军服役经历的总统

回京历史梦
2026-10-26 10:49:29
机动车年检大势已定?从2027年开始,私家车年检可能面临5大变化

机动车年检大势已定?从2027年开始,私家车年检可能面临5大变化

刘哥谈体育
2026-11-15 13:22:01
性生活是不是人的刚需?网友说:男性性生活是刚需,女性不是!

性生活是不是人的刚需?网友说:男性性生活是刚需,女性不是!

黯泉
2026-11-09 17:39:59
藏南风向开始变了!60个村子已团结起来,直接拒绝与印度当局谈判

藏南风向开始变了!60个村子已团结起来,直接拒绝与印度当局谈判

触摸史迹
2026-11-14 01:22:48
宏远速递!陈老板最新决定,又一强援将加盟,徐杰深夜发声!

宏远速递!陈老板最新决定,又一强援将加盟,徐杰深夜发声!

体坛卡卡说
2026-11-16 15:24:45
王忠林虽然落马了,但他带给人们的伤痛一直都在

王忠林虽然落马了,但他带给人们的伤痛一直都在

神不隆通
2026-11-16 16:05:22
敖海清主任:苹果煮水太厉害了!睡前一碗睡得香气血足

敖海清主任:苹果煮水太厉害了!睡前一碗睡得香气血足

蜡笔小小子
2026-11-15 15:10:25
震惊!网传浙江一新员工父亲联系HR提多项要求:愿每月自掏5000给女儿加薪,请假外出需向他报备

震惊!网传浙江一新员工父亲联系HR提多项要求:愿每月自掏5000给女儿加薪,请假外出需向他报备

火山詩话
2026-11-16 16:02:11
凯恩客场7连斩,贝林献精妙助攻,英格兰3-2破西班牙43场不败金身

凯恩客场7连斩,贝林献精妙助攻,英格兰3-2破西班牙43场不败金身

钉钉陌上花开
2026-11-16 05:47:06
陈百祥回应谭咏麟蟹宴没请他:我吃蟹的时候也没叫他

陈百祥回应谭咏麟蟹宴没请他:我吃蟹的时候也没叫他

情感大头说说
2026-11-16 02:53:25
恭喜杨瀚森!开拓者或将小杨送至老鹰,有望跻身首发阵容

恭喜杨瀚森!开拓者或将小杨送至老鹰,有望跻身首发阵容

湖人侃球师
2026-11-15 17:08:01
全美所有机场停飞的原因找到了,让人笑掉大牙

全美所有机场停飞的原因找到了,让人笑掉大牙

铁锤侃侃而谈
2026-11-16 09:50:47
“温太医”张晓龙一家五口罕同框!两个女儿与三胎宝宝现身,妻子低调同行

“温太医”张晓龙一家五口罕同框!两个女儿与三胎宝宝现身,妻子低调同行

动物奇奇怪怪
2026-11-16 13:51:22
哈登开局又拉胯?美媒4笔方案交易!热火换维金斯,去火箭联手KD

哈登开局又拉胯?美媒4笔方案交易!热火换维金斯,去火箭联手KD

老郎体育汇
2026-11-16 14:51:38
10月国民经济运行总体平稳、向新向优

10月国民经济运行总体平稳、向新向优

新华社
2026-11-16 10:06:29
勾引马斯克挺难的,正如他前妻所言:14个孩子的母亲都被他称为“生育机器”

勾引马斯克挺难的,正如他前妻所言:14个孩子的母亲都被他称为“生育机器”

照见古今
2026-11-12 14:48:00
突发!逆转,黄仁勋计划回英伟达!

突发!逆转,黄仁勋计划回英伟达!

财经要参
2026-11-16 15:30:05
彭加木失踪四十多年后现身美国?真相浮出水面!当年中央严令追查,背后内情让人背脊发凉

彭加木失踪四十多年后现身美国?真相浮出水面!当年中央严令追查,背后内情让人背脊发凉

磊子讲史
2026-11-10 15:53:31
山姆、盒马、永辉都在降!价格跌到近10年最低 | 早安 珠海

山姆、盒马、永辉都在降!价格跌到近10年最低 | 早安 珠海

珠海发布
2026-11-16 07:39:07
0+0+0+0+0!申请交易杨瀚森!脸都不要了……

0+0+0+0+0!申请交易杨瀚森!脸都不要了……

江启
2026-11-15 14:58:55
2026-11-16 17:47:00
钛媒体APP incentive-icons
钛媒体APP
独立财经科技媒体
142059文章数 862714关注度
往期回顾 全部

教育要闻

10金31银3铜!河南学子在物理、化学奥赛全国决赛斩获优异成绩

头条要闻

上任2个月尤尼斯在街头遭暗杀身亡 知情人:被以"斩首"

头条要闻

上任2个月尤尼斯在街头遭暗杀身亡 知情人:被以"斩首"

体育要闻

NBA开赛最大惊喜,是他们?

娱乐要闻

陈晓楠对话厉娜和许飞引全网热议

财经要闻

10万人逼宫英伟达,黄仁勋要复职了?

科技要闻

历史头一回!马斯克用"筷子"夹住太空飞船

汽车要闻

更豪华更好开 问界新M8细节升级见真章

态度原创

数码
游戏
本地
旅游
军事航空

数码要闻

满电开躁!11月16日,航嘉满电青年计划约你西南交大见!

传《GTA6》主线约50个小时 全成就大约200个小时

本地新闻

乌兰察布:以前种土豆,现在种Token

旅游要闻

秋假遛娃剑门关,全程17000步,6个小时,喜提废腿体验!

军事要闻

哈马斯拉法旅指挥官死于以军空袭

无障碍浏览 进入关怀版